Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Trial Profile

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary) ; Ibrutinib
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRANSCEND-CLL-004
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 04 Dec 2018 Results of preliminary safety, pharmacokinetics and efficacy presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Dec 2018 According to a Celgene Corporation media release, initial data from the study were presented at the 60thAmerican Society of Hematology (ASH) Annual Meeting and Exposition.
    • 02 Dec 2018 Interim results (n=16) presented in a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top